Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric AdenocarcinomaPeter Thuss‐Patience, Mascha Binder, Frank Kullmann et al.|JAMA Network Open|2024Cited by 13
Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).Dominik Paul Modest, Tanja Trarbach, Meinolf Karthaus et al.|Journal of Clinical Oncology|2021Cited by 6
Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Peter Thuss‐Patience, Alexander Stein, Anica Högner et al.|Journal of Clinical Oncology|2022Cited by 4
Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).Peter Thuss‐Patience, Mascha Binder, Anica Högner et al.|Journal of Clinical Oncology|2023Cited by 0